CRVS - Company ID 0001626971
Corvus Pharmaceuticals, Inc. (CRVS) reported net income of -$15.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$15.30M | +75.4% |
| FY 2024 | -$62.30M | -130.7% |
| FY 2023 | -$27.00M | +34.6% |
| FY 2022 | -$41.31M | +4.5% |
| FY 2021 | -$43.24M | -621.3% |
| FY 2020 | -$6.00M | +87.2% |
| FY 2019 | -$46.67M | +0.6% |
| FY 2018 | -$46.94M | +15.7% |
| FY 2017 |
Corvus Pharmaceuticals, Inc. (CRVS) reported net income of -$15.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Corvus Pharmaceuticals, Inc.'s net income declined from -$161.00K to -$15.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$55.66M |
| -53.0% |
| FY 2016 | -$36.38M | -16.1% |
| FY 2015 | -$31.34M | -19362.7% |
| FY 2014 | -$161.00K | - |